(San Diego, December 18, 2024) – Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout, today announced that it has enrolled more than 50% of patients in its pivotal Phase 3 REDUCE 2 trial evaluating AR882 for the reduction of sUA in gout patients.
“We are excited by the momentum we have seen in the REDUCE 2 study since enrolling the first patient in July 2024. This is a reflection of the commitment of our team and clinical collaborators as we seek to redefine the standard of care for patients with gout,” said Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics. “With our REDUCE 2 study well ahead of its projected schedule, we expect to complete enrollment in the first half of 2025, and in parallel, plan to initiate our REDUCE 1 study, a replicate Phase 3 study in the first quarter of 2025.”
Dr. Robert T. Keenan, MD, MPH, Chief Medical Officer at Arthrosi Therapeutics added, “There remains a large unmet need for a safe and convenient gout treatment, which can provide clinical benefit with reduction of tophi and flares. We remain highly encouraged by the potential of AR882, and believe that our pivotal phase 3 program will support a comprehensive New Drug Application to the U.S. Food and Drug Administration as we seek to improve the lives of all gout patients.”
